<DOC>
	<DOCNO>NCT00633542</DOCNO>
	<brief_summary>This randomize , multicentre study aim compare standard maintenance therapy Interferon-Dexamethasone experimental therapy base Thalidomide-Dexamethasone patient multiple myeloma respond ThaDD induction therapy</brief_summary>
	<brief_title>Maintenance Therapy After Thalidomide-Dexamethasone ( ThaDD ) Multiple Myeloma ( MM )</brief_title>
	<detailed_description>Thalidomide already use maintenance and/or consolidation high-dose therapy follow autologous stem cell transplantation . Despite number phase II III study issue right dose duration thalidomide subset patient benefit yet settle We explore maintenance therapy thalidomide , dexamethasone pegylated liposomal doxorubicin call ThaDD protocol . Patients de novo relapse MM obtain least minor response 4 6 ThaDD course , randomize receive standard maintenance therapy IFN 3 MU 3 time week experimental maintenance therapy thalidomide 100 mg per day relapse intolerable side effect . Both group also receive pulsed dexamethasone 20 mg 4 day month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>patient newly diagnose advanced multiple myeloma achieve least minimal response induction ThaDD regimen Written consent peripheral neuropathy &gt; = grade 2 neutropenia &lt; 1000/mcl thrombocytopenia &lt; 50000/mcl severe depression organ disfunction &gt; grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>thalidomide</keyword>
	<keyword>maintenance</keyword>
	<keyword>interferon</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>newly diagnose multiple myeloma</keyword>
	<keyword>relapsed refractory multiple myeloma</keyword>
</DOC>